Key clinical point: Baroreflex activation therapy for HFrEF brings impressive improvements in quality of life and functional capacity.

Major finding: Forty-three percent of women and 24% of men were categorized as double super responders to baroreflex activation therapy for HFrEF.

Study details: This was the 6-month outcome of a randomized trial of optimal medical therapy alone or with baroreflex activation therapy in 264 HFrEF patients.

Disclosures: The presenter reported serving as a consultant to CVRx, the study sponsor, as well as half a dozen other medical device and pharmaceutical companies.